EMERGENT BIOSOLUTIONS INC. Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
EMERGENT BIOSOLUTIONS INC. (EBS) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $1.50 million for the 12-month period ending 2022-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2025-03-04
- EMERGENT BIOSOLUTIONS INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2022 was $1.50M.
- EMERGENT BIOSOLUTIONS INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2019 was $0.00.
- EMERGENT BIOSOLUTIONS INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2018 was $0.00.
- EMERGENT BIOSOLUTIONS INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2017 was $0.00.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month |
|---|---|
| 2022-12-31 | $1.50M 10-K · filed 2025-03-04 |
| 2019-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-22 |
| 2015-12-31 | $0.00 10-K · filed 2018-02-23 |
| 2014-12-31 | $0.00 10-K · filed 2017-02-28 |
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 |
| 2012-12-31 | $65.00K 10-K · filed 2015-03-09 |
| 2011-12-31 | $61.00K 10-K · filed 2014-03-10 |
| 2010-12-31 | $175.00K 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |